Repligen stock rises on positive Q4 results and 2025 outlook

Published 20/02/2025, 20:50
© Reuters.

Investing.com -- Shares of Repligen (NASDAQ: NASDAQ:RGEN) climbed 9% following the release of its fourth-quarter earnings and future financial guidance that exceeded analysts’ expectations. The life sciences company, known for its bioprocessing technology, reported a fourth-quarter earnings per share (EPS) of $0.44, which was $0.03 higher than the consensus estimate of $0.41. Revenue for the quarter was reported at $168 million, marginally surpassing the consensus estimate of $167.67 million.

The company has also provided an optimistic forecast for fiscal year 2025, expecting EPS to be between $1.67 and $1.76, compared to the consensus estimate of $1.71. Revenue projections for the same period are set at $685-710 million, against the consensus forecast of $692.8 million.

Repligen’s performance in the fourth quarter saw a 13% increase in revenue excluding COVID-related revenue, despite a two-point currency headwind. Orders surpassed revenue by 6%, driven by growth in the Filtration and Analytics franchises. The company also reported a significant sequential increase in revenues from CDMOs and capital equipment, which rose approximately 20% and 30%, respectively.

President and CEO Olivier Loeillot expressed confidence in achieving the company’s 2025 guidance, citing strong order momentum in the second half of the year. Repligen’s recent acquisition of Tantti Laboratory Inc. and the launch of innovative products like the AVIPure® dsRNA resin are expected to contribute to future growth.

Jefferies analyst Matthew Stanton provided a positive outlook, stating, "With stock off ~15% since the Sartorius print a few weeks ago, a solid 4Q showing, ’25 guide slightly ahead and largely upbeat order commentary was plenty for shares to move higher." Stanton’s comment reflects the market’s reaction to Repligen’s solid financial performance and the company’s potential for growth in the coming year.

Investors seem to be responding favorably to Repligen’s recent achievements and future prospects, as reflected in the stock’s upward movement. The company’s focus on expanding its product offerings and commitment to sustainability, highlighted in its 2023 Sustainability report, also play a role in shaping its positive market image. As Repligen continues to navigate the bioprocessing market, its strategic initiatives and financial guidance set a promising course for 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.